AZN Q1 Earnings and Sales Beat, Key Drugs Offset Generic PressureZacks Investment Research • 04/29/26
AstraZeneca sticks to its guns after strong first-quarter revenue growthProactive Investors • 04/29/26
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosusBusiness Wire • 04/27/26
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key MetricsZacks Investment Research • 04/24/26
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 04/23/26
AstraZeneca's tozorakimab treble puts $5bn sales ceiling in sight, says CitiProactive Investors • 04/21/26
AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trialProactive Investors • 04/21/26
AstraZeneca's Ultomiris reduces urine protein in late-stage trial of rare kidney diseaseReuters • 04/21/26
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPDBusiness Wire • 04/20/26
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 04/15/26
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upsideProactive Investors • 04/10/26
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?Zacks Investment Research • 04/09/26
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drugProactive Investors • 04/07/26
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And ReturnsSeeking Alpha • 04/05/26